Gregory Renza Analyst Performance

Gregory Renza, M.D., is a Director and Senior Biotechnology Research Analyst at RBC Capital Markets, specializing in biotechnology equity research with coverage across over 38 healthcare and biotech companies including Exelixis and Spruce Biosciences. He maintains a track record of 551 ratings, an average price target met ratio of 38.2%, and a documented best-performing recommendation yielding a 61.5% return on Spruce Biosciences within one day; his overall success rate ranks near 39% with an average return of 1.77%. Dr. Renza joined RBC in 2017 after holding analyst positions at Jefferies and Wells Fargo Securities, and began his career in consulting and strategy roles at Booz & Company and CVS Caremark. He holds an A.B. in Biology and an M.D. from Brown University, and is recognized for his deep analytical expertise and impactful industry insights.